Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

Rhea-AI Summary

BioArctic (Nasdaq Stockholm: B) issued 78,000 Class B shares in February 2026 under the 2019/2028 stock option program. As of February 27, 2026 the company had 88,719,485 shares: 74,319,489 listed Class B and 14,399,996 unlisted Class A. A shares carry ten votes; B shares carry one vote, giving a total of 218,319,449 votes.

Contact details for investor relations are provided for further inquiries.

Key Figures

New Class B shares: 78,000 shares Options exercised: 78,000 options Total shares: 88,719,485 shares +5 more

8 metrics

New Class B shares 78,000 shares Issued in February 2026 via 2019/2028 stock option program

Options exercised 78,000 options Stock options of series 2019/2028 exercised in February 2026

Total shares 88,719,485 shares Total BioArctic shares outstanding as of Feb 27, 2026

Class B shares 74,319,489 shares Listed Class B shares as of Feb 27, 2026

Class A shares 14,399,996 shares Unlisted Class A shares as of Feb 27, 2026

Votes per A share 10 votes Voting power attached to each Class A share

Votes per B share 1 vote Voting power attached to each Class B share

Total votes 218,319,449 votes Total voting rights in the company as of Feb 27, 2026

Market Reality Check

Price: $50.68 Vol: Volume 15,447,621 is 0.86...

normal vol

$50.68 Last Close

Volume Volume 15,447,621 is 0.86x the 20-day average of 18,020,127, indicating slightly below-typical trading activity. normal

Technical Price at 50.365 is trading above the 200-day MA of 32.66 and about 7.91% below the 52-week high of 54.69.

Peers on Argus

The stock gained 1.08% while key gold peers also traded higher: WPM +3.09%, FNV ...

The stock gained 1.08% while key gold peers also traded higher: WPM +3.09%, FNV +2.24%, AU +2.91%, AEM +3.06%, and KGC +3.23%, indicating a broader positive move in the group.

Historical Context

5 past events · Latest: Feb 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 24	Leadership changes	Neutral	+0.2%	Executive appointments to legal, policy and global affairs roles.
Feb 11	Earnings presentation	Neutral	+1.5%	Announcement of timing and format for Q4 2025 report presentation.
Feb 06	Royalty update	Positive	+2.7%	Leqembi Q4 2025 sales driving higher royalty revenue to BioArctic.
Feb 05	Earnings results	Positive	-7.2%	Record 2025 revenue, cash flow and production metrics at Barrick.
Feb 05	Dividend & buybacks	Positive	-7.2%	Increased dividend and sizable share repurchases with new payout policy.

Pattern Detected

Recent news has often seen positive reactions to operational and royalty updates, while seemingly strong earnings and capital return announcements coincided with notable negative moves.

Recent Company History

Over the last few months, news tied to this ticker spans both BioArctic and Barrick. BioArctic updates included a Q4 report presentation invite on Feb 18, 2026 and Leqembi-related royalties of SEK 127 million, which saw share reactions of +1.47% and +2.71%. Barrick items covered leadership changes, record 2025 results, and a sharply increased dividend plus buybacks. Despite strong financials and higher payouts, Barrick-related earnings and dividend news were followed by -7.16% moves, highlighting prior divergence between fundamentals headlines and price.

Market Pulse Summary

This announcement formalizes BioArctic’s updated capital structure following the exercise of 78,000 ...

Analysis

This announcement formalizes BioArctic’s updated capital structure following the exercise of 78,000 stock options from the 2019/2028 program. As of February 27, 2026, the company reports 88,719,485 shares outstanding and 218,319,449 votes, clarifying the split between Class A and B shares and their voting power. Investors can track how these incremental changes interact with prior milestones such as Leqembi royalty growth and upcoming financial reporting.

Key Terms

stock option program, eu market abuse regulation

2 terms

stock option program financial

"issued 78,000 Class B shares during February for delivery of shares to participants in the 2019/2028 stock option program"

A stock option program is a company plan that gives employees or directors the right to buy company shares at a fixed price for a set period, similar to a coupon that lets you buy a product later at today’s price. It matters to investors because such programs can align staff incentives with company performance and help retain talent, but they also increase the number of shares over time, which can dilute existing ownership and affect earnings per share.

eu market abuse regulation regulatory

"information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation"

A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.

AI-generated analysis. Not financial advice.

STOCKHOLM, Feb. 27, 2026 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company issued 78,000 Class B shares during February for delivery of shares to participants in the 2019/2028 stock option program resolved at the Annual General Meeting on May 9, 2019. The shares were issued through an exercise of 78,000 stock options of series 2019/2028.

As of February 27, 2026, the last trading day of the month, the total number of shares in BioArctic AB amounted to 88,719,485 shares, of which 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares. The A share has ten votes per share and the B share has one vote per share. The total number of votes in the company amounts to 218,319,449.

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on February 27, 2026, at 18.30 CET.

For more information, please contact:
Oskar Bosson, VP Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.com 
Tel: +46 704 10 71 80

Anders Martin-Löf, CFO
E-mail: anders.martin-lof@bioarctic.com 
Telephone +46 70-683 79 77
 

About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson-related diseases and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bioarctic/r/number-of-shares-and-votes-in-bioarctic-ab--publ--as-of-february-27--2026,c4314113

The following files are available for download:

https://mb.cision.com/Main/9978/4314113/3956238.pdf

Number of shares and votes in BioArctic AB (publ) as of February 27, 2026

View original content:https://www.prnewswire.com/news-releases/number-of-shares-and-votes-in-bioarctic-ab-publ-as-of-february-27-2026-302699840.html

SOURCE BioArctic

FAQ

How many shares did BioArctic (B) issue in February 2026 under the 2019/2028 option program?

BioArctic issued 78,000 Class B shares in February 2026. According to BioArctic, these shares were delivered via exercise of 78,000 stock options from the 2019/2028 series resolved at the Annual General Meeting on May 9, 2019.

What is the total number of outstanding shares in BioArctic (B) as of February 27, 2026?

As of February 27, 2026, BioArctic had 88,719,485 shares outstanding. According to BioArctic, that total comprises 74,319,489 listed Class B shares and 14,399,996 unlisted Class A shares.

How many votes does each class of BioArctic (B) share carry as of Feb 27, 2026?

Class A shares carry 10 votes each and Class B shares carry 1 vote. According to BioArctic, this voting structure results in a combined total of 218,319,449 votes as of February 27, 2026.

What is the effect on total votes after BioArctic (B) issued 78,000 Class B shares in February 2026?

Issuing 78,000 Class B shares increased the share count but had a limited vote impact. According to BioArctic, total votes stand at 218,319,449 as of February 27, 2026, reflecting the existing A/B voting ratio.

Were the February 2026 share issues in BioArctic (B) part of an approved shareholder program?

Yes, the February 2026 share issuance followed the 2019/2028 stock option program approved at the AGM on May 9, 2019. According to BioArctic, shares were issued through exercise of options from that authorized series.

Where can investors get more information about BioArctic's share count update on Feb 27, 2026?

Investors can contact BioArctic's investor relations for details. According to BioArctic, contact persons listed include Oskar Bosson (VP Communications and IR) and Anders Martin-Löf (CFO) with provided email addresses and telephone numbers.